UA86056C2 - Твердый дисперсионный состав базедоксифена ацетата, способ его получения (варианты) и применение (варианты) - Google Patents

Твердый дисперсионный состав базедоксифена ацетата, способ его получения (варианты) и применение (варианты)

Info

Publication number
UA86056C2
UA86056C2 UAA200610673A UAA200610673A UA86056C2 UA 86056 C2 UA86056 C2 UA 86056C2 UA A200610673 A UAA200610673 A UA A200610673A UA A200610673 A UAA200610673 A UA A200610673A UA 86056 C2 UA86056 C2 UA 86056C2
Authority
UA
Ukraine
Prior art keywords
variants
preparation
solid dispersion
bazedoxifene acetate
dispersion formulations
Prior art date
Application number
UAA200610673A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Сиэд М. Шах
Кадум А. Али
Крисиіан Л. Офслагер
Магди Б. Фоузи
Original Assignee
Уайет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965020&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA86056(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Уайет filed Critical Уайет
Publication of UA86056C2 publication Critical patent/UA86056C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
UAA200610673A 2004-04-08 2005-04-07 Твердый дисперсионный состав базедоксифена ацетата, способ его получения (варианты) и применение (варианты) UA86056C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56045204P 2004-04-08 2004-04-08

Publications (1)

Publication Number Publication Date
UA86056C2 true UA86056C2 (ru) 2009-03-25

Family

ID=34965020

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200610673A UA86056C2 (ru) 2004-04-08 2005-04-07 Твердый дисперсионный состав базедоксифена ацетата, способ его получения (варианты) и применение (варианты)

Country Status (20)

Country Link
US (1) US20050227966A1 (https=)
EP (1) EP1732528A1 (https=)
JP (1) JP2007532557A (https=)
CN (1) CN1942177B (https=)
AR (1) AR048534A1 (https=)
AU (1) AU2005232640B2 (https=)
BR (1) BRPI0509381A (https=)
CA (1) CA2561124A1 (https=)
CR (1) CR8617A (https=)
EC (1) ECSP066912A (https=)
GT (1) GT200500083A (https=)
IL (1) IL178235A0 (https=)
MX (1) MXPA06011685A (https=)
NO (1) NO20065051L (https=)
PA (1) PA8629301A1 (https=)
PE (1) PE20060167A1 (https=)
RU (1) RU2400227C2 (https=)
TW (1) TW200605863A (https=)
UA (1) UA86056C2 (https=)
WO (1) WO2005099677A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002823A2 (en) * 2005-06-29 2007-01-04 Wyeth Formulations of conjugated estrogens and bazedoxifene
JP2009506053A (ja) * 2005-08-24 2009-02-12 ワイス 酢酸バゼドキシフェン製剤
AU2012275036B2 (en) * 2005-08-24 2016-05-19 Wyeth Llc Bazedoxifene acetate formulations and manufacturing process thereof
CZ302358B6 (cs) * 2007-07-25 2011-03-30 Zentiva, A. S. Nové soli bazedoxifenu
US20100016290A1 (en) * 2008-02-11 2010-01-21 Livius Cotarca Amorphous polymorph of bazedoxifene acetate
AU2009223014A1 (en) * 2008-03-11 2009-09-17 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
CN102552103B (zh) * 2010-12-20 2013-11-20 西安力邦医药科技有限责任公司 拉米夫定固体分散体、其制备方法、药物组合物和用途
WO2013056108A2 (en) * 2011-10-14 2013-04-18 Array Biopharma Inc. Solid dispersion
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
CN103845336B (zh) * 2014-03-24 2016-03-09 江苏知原药业有限公司 一种性能优异的乙酸巴多昔芬组合物
MX2017011469A (es) * 2015-03-10 2018-01-23 Shionogi Inc Dispersiones sólidas.
CN113244240A (zh) * 2021-05-26 2021-08-13 深圳市人民医院 醋酸巴多昔芬在治疗急性髓系白血病药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5332727A (en) * 1993-04-29 1994-07-26 Birkmayer U.S.A. Stable, ingestable and absorbable NADH and NADPH therapeutic compositions
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5919800A (en) * 1995-02-28 1999-07-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US5780497A (en) * 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US6005102A (en) * 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
SG162615A1 (en) * 2002-06-13 2010-07-29 Wyeth Corp Bazedoxifene treatment regimens
DE602006010343D1 (de) * 2005-03-31 2009-12-24 Wyeth Corp Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon
WO2007002823A2 (en) * 2005-06-29 2007-01-04 Wyeth Formulations of conjugated estrogens and bazedoxifene
JP2009506053A (ja) * 2005-08-24 2009-02-12 ワイス 酢酸バゼドキシフェン製剤

Also Published As

Publication number Publication date
CN1942177B (zh) 2011-05-25
RU2006132179A (ru) 2008-05-20
GT200500083A (es) 2005-10-31
JP2007532557A (ja) 2007-11-15
RU2400227C2 (ru) 2010-09-27
NO20065051L (no) 2006-11-07
PA8629301A1 (es) 2006-10-13
CA2561124A1 (en) 2005-10-27
ECSP066912A (es) 2006-12-20
AR048534A1 (es) 2006-05-03
TW200605863A (en) 2006-02-16
MXPA06011685A (es) 2006-12-14
AU2005232640A1 (en) 2005-10-27
IL178235A0 (en) 2007-03-08
PE20060167A1 (es) 2006-04-20
EP1732528A1 (en) 2006-12-20
BRPI0509381A (pt) 2007-09-18
AU2005232640B2 (en) 2011-07-28
WO2005099677A1 (en) 2005-10-27
US20050227966A1 (en) 2005-10-13
CN1942177A (zh) 2007-04-04
CR8617A (es) 2007-08-28

Similar Documents

Publication Publication Date Title
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
UA86056C2 (ru) Твердый дисперсионный состав базедоксифена ацетата, способ его получения (варианты) и применение (варианты)
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
MY148634A (en) Pyridazinone derivatives
MX2007014892A (es) Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
TW200738281A (en) Bazedoxifene acetate formulations
SG151331A1 (en) Crystalline polymorph of a bazedoxifene acetate
JO2761B1 (en) Derivatives of alcohols 1-phenyl-2-pyridinealkyl as inhibitors
WO2006069363A3 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2008002570A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
WO2008002569A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
UA83311C2 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2008002571A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
MX2009003227A (es) Moduladores de los receptores de glutamato metabotropicos 5(mglur5).
AU2003228770A1 (en) Substituted pyrazolopyrimidines
TW200621235A (en) Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms)
UA86055C2 (ru) Кристаллическая форма в базедоксифена ацетата
MX2010001851A (es) Derivados de indol-2-ona disustituidos en 3, su preparacion y uso terapeutico.
MEP1008A (xx) 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
UA96277C2 (en) Benzimidazole derivatives
UA85703C2 (en) Crystalline polymorph of bazedoxifene acetate
TW200745133A (en) New compounds II
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof
TW200706173A (en) Oral composition comprising carbamylating agent